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Objective: Seizures often occur in patients with primary brain tumor (BT). The aim of this studywas to determine
if there is an association between the time of occurrence of seizures during the course of BT and survival of these
patients.
Methods: This retrospective cohort study at Henry Ford Hospital, an urban tertiary referral center, included all
patients whowere diagnosedwith primary BTs at Henry Ford Health System between January 2006 and Decem-
ber 2014. Timing of seizure occurrence, if occurred at presentation or after the tumor diagnosis during follow-up
period, in different grades of BTs, and survival of these patients were analyzed.
Results: Of the 901 identified patients, 662 (53% male; mean age: 56 years) were included in final analysis, and
seizures occurred in 283 patients (43%). Patients with World Health Organization (WHO) grade III BT with sei-
zures as a presenting symptom only had better survival (adjusted hazard ratio (HR): 0.27; 95% confidence inter-
val (CI), 0.11–0.67; P = 0.004). Seizures that occurred after tumor diagnosis only (adjusted HR: 2.11; 95% CI,
1.59–2.81; P b 0.001) in patients with WHO grade II tumors (adjusted HR: 3.41; 95% CI, 1.05–11.1; P = 0.041)
and WHO grade IV tumors (adjusted HR: 2.14; 95% CI, 1.58–2.90; P b 0.001) had higher mortality. Seizures
that occurred at presentation and after diagnosis also had higher mortality (adjusted HR: 1.34; 95% CI, 1.00–
1.80; P = 0.049), in patients with meningioma (adjusted HR: 6.19; 95% CI, 1.30–29.4; P = 0.021) and grade III
tumors (adjusted HR: 6.19; 95% CI, 2.56–15.0; P b 0.001).
Conclusion: Seizures occurred in almost half of the patientswith BTs. The association between seizures in patients
with BT and their survival depends on the time of occurrence of seizures, if occurring at presentation or after
tumor diagnosis, and the type of tumor. Better survival was noted in patients with WHO grade III BTs who had
seizures at presentation at the time of diagnosis, while higher mortality was noted in WHO grade II tumors
who had seizure at presentation and after tumor diagnosis, and in grade IV tumors after tumor diagnosis.
© 2020 Elsevier Inc. All rights reserved.
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1. Introduction
Epileptic seizures in patients with primary brain tumors (BTs) are
considered a valuable prognostic attribute that also significantly disrupt
health-related quality of life (HRQOL) [1]. Unfortunately, seizures are
commonly encountered in patients with primary BTs, with prevalence
ranging from 20 to 80%, depending on the type and location of the
tumor [2]. Slow-growing tumors have a higher incidence of seizures
than rapidly growing tumors, probably because of earlier death in the
latter cases and underlying molecular mechanisms such as IDH1 muta-
tions [3]; however, meningioma, which is typically a grade I tumor, has
shown low rates [2,4–6]. Survival andHRQOL,which includes functional
independence, are of paramount importance across health particularly
at the intersection of neuroscience and oncology [7,8].
Limited studies exist assessing seizures as prognostic indicators in
patients with BT. In patients with seizures, improved overall survival
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(OS) has been described in patients with high-grade gliomas [9] while
others report better survival rates in those with low-grade glioma,
although the reasons remain unclear [10]. Furthermore, seizures at pre-
sentation in high-grade BT are associated with prolonged survival [11],
while those in low-grade BT in elderly population are associated with
severe course [12]. There remains conflicting evidence coupled with
high-observed variability in the literature of seizure prevalence strati-
fied by BT type, grade, or location [2]. Overall, the studies published,
thus far, fail to demonstrate the role of the timing of seizure occurrence
at presentation or during the course of the diagnosis on the survival in
patients with BT.
The aim of this study was to comprehensively analyze the associa-
tion of OS with experiencing a seizure as a BT presenting symptom at
diagnosis and/or developing seizures following diagnosis in a large
cohort of patients with multiple BT types.
2. Methods
We report our study in accordance with the Strengthening the
Reporting of Observational Studies in Epidemiology (STROBE) state-
ment, following Enhancing the Quality and Transparency of Health
Research (EQUATOR) reporting guidelines [13].
2.1. Study design and population
This is a retrospective cohort study conducted at Henry Ford Health
System in Detroit, MI, USA, a collaborative experience of the Henry Ford
Comprehensive Epilepsy Program and the Hermelin Brain Tumor
Center. We identified patients with a diagnosis of primary tumor of
the central nervous system utilizing the Henry Ford Hospital (HFH)
Tumor Registry. Adult patients (age ≥18 years) who were newly diag-
nosed with a primary BT between January 1, 2006 and December 31,
2014 were included in the study. Patients who had tumor in the spine
or brainstem, who diedwithin twomonths after diagnosis, or whose in-
formation regarding tumor type or a history of seizure at timeof diagno-
sis or during follow-upwas not available were excluded. This studywas
approved by Henry Ford Health System Institutional Review Board (IRB
number 10298).
2.2. Data collection
Data regarding date of tumor diagnosis, date of death, and date of
last follow-up were taken from the HFH Tumor registry. Data collected
from the electronic medical record (EMR) included patient demo-
graphics, prior history of epilepsy, specific type, and grade of BT (accord-
ing to the 2016 World Health Organization (WHO) Classification of
Tumors of the Central Nervous System) [14], tumor location, seizures
as a presenting symptom of BT, seizures occurring after tumor diagnosis
and the date of such seizures, antiseizure drugs (ASDs), all treatments
received for BT, and date last seen in the clinic. Additional confirmation
of tumor type and grade and follow-up informationwere collected from
the Hermelin Brain Tumor Center Registry.
2.3. Outcomes
The primary outcome was time to death during follow-up that was
defined as the time between date of tumor diagnosis and date of
death, or last follow-up. The secondary outcomes were seizure preva-
lence stratified by tumor type and location, and other factors that may
be associated with seizures in patients with BTs.
2.4. Statistical analysis
Patients were divided into four seizure groups depending on the
presence of seizures and the time of seizure occurrence in relation to
BT diagnosis. Specifically, the four groups were no seizures, seizures as
a presenting symptom only, seizures that occurred after diagnosis
only, and both seizures as a presenting symptom and occurring after di-
agnosis. Chi-square tests were done to assess the association of seizures
with demographic information, type of BT, treatments received, and BT
location. Analysis of variance (ANOVA) was done to compare age at di-
agnosis among the seizure groups. Kaplan–Meier estimates were used
to compute the median survival time (time corresponding to survival
of 50%) for the different tumor types. Cox proportional hazards regres-
sion analyses with time-dependent covariates were done to assess the
relationship between seizure groups and OS with hazard ratios (HR)
and 95% confidence intervals (CIs) being calculated. The reference
group for the HR was the no seizure group. Additional factors that
were associated both with seizure occurrence and survival were in-
cluded in the multivariate regression models. In addition, because of
the known survival differences among the tumor grades, the Cox re-
gression models were stratified by tumor grade for all patients and
were done for each specific tumor grade.Modified Kaplan–Meier curves
using time-dependent covariates for the seizure groups were done to
assess OS experience within each tumor grade. No imputation was
done for any missing information. All testing was set at the 0.05 alpha
level. SAS version 9.4 was used for the data analyses.
3. Results
Of 901 patients identified to have a diagnosis of primary central ner-
vous system tumor in the Henry Ford Hospital tumor registry between
January 1, 2006 and December 31, 2014, 239 patients were not eligible,
for having infratentorial tumor (n=15), deathwithin twomonths after
diagnosis (n = 31) or insufficient clinical information (n = 193), leav-
ing 662 patientswith primary BT in thefinal analysis. Overall, 283 (43%)
patients with BT experienced seizures, 110 (17%) had seizures that oc-
curred as a presenting symptom of the tumor only, 81 (12%) developed
seizures during follow-up after BT diagnosis only, and 92 (14%) experi-
enced seizures both at presentation and during follow-up. The remain-
ing 379 (57%) patients did not experience any seizures.
3.1. Baseline characteristics
The mean age of the eligible patients was 56 years, with 53% male,
83% Caucasian, and 12% were African American (Table 1).
Patients with seizure as a presenting symptomwere younger (54 ±
15 years vs 57±14 years, P=0.009) andmore likely to bemale (63% vs
49%, P b 0.001) compared with those without a seizure as a presenting
symptom. The overall difference in the racial distributions among
the seizures groups was significant with patients with seizures during
both time points more likely to be African American (P = 0.014,
Table 1). A prior history of epilepsywas present in 3% of overall patients,
with patients having seizures during both time points exhibiting the
highest rate (11%) of seizure followed by patientswith seizures as a pre-
senting symptom (5%) (P b 0.001, Table 1).
3.2. Grading and location of tumor
The four defined seizure phenotypic groups analyzed byWHO grad-
ing showed that the majority BTs were WHO grade IV (56%), all of
which were glioblastomas; followed by WHO grade I (21%), all of
whichweremeningioma;WHO grade II (13%), which included astrocy-
toma, oligodendroglioma, and oligoastrocytoma; and WHO grade III
(10%) including anaplastic astrocytoma, anaplastic oligodendroglioma,
and anaplasticmeningioma (Table 2). TheWHOgradingwas associated
with the patterns of seizures (P b 0.001, Table 2)with the highest rate of
seizure in patientswith aWHOgrade II tumor (34% had seizure as a pre-
senting symptomonly, and25% had seizures both as a presenting symp-
tom and during follow-up) and the lowest rate of seizure in patients
with WHO I, meningioma (24% had a seizure at presentation and/or
during follow-up).
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The distribution of tumor location was 46% frontal, 34% temporal,
26% parietal, 9% occipital, 4% deep midline, 2% cerebellum, 2% insular,
and 16% other location (Table 3). Patients with seizures were more
likely to have a tumor in the cortical region (93% vs 85%, P = 0.001)
compared with those without seizures. Patients without a seizure
were more likely to have tumors in the cerebellum (3% vs 0%, P =
0.018) compared with patients with a seizure at either time point,
while patients who had seizure occurring after tumor diagnosis only
were more likely to have tumor in the parietal lobe (41% vs 24%, P =
0.001) compared with the other seizure groups.
3.3. Treatment for brain tumor
Antiseizure drugs were prescribed immediately after tumor diagno-
sis in 500 (76%) of the patients regardless of presence of seizure. Of the
460 patients without seizure as a presenting symptom, 302 (66%) of
Table 2
Seizure occurrence in patients with different World Health Organization Tumor grade.
Seizure occurrence Meningioma
(n = 139)
WHO Grade II tumora
(n = 85)
WHO Grade III tumorb
(n = 67)
WHO Grade IV tumorc
(n = 371)
P value
No seizures 105 (76) 26 (31) 40 (60) 208 (56) b0.001
Seizure as a presenting symptom only 13 (9) 29 (34) 16 (24) 52 (14)
Seizure as a presenting symptom and seizure occurred after tumor diagnosis 13 (9) 21 (25) 8 (12) 50 (13)
Seizure occurred after tumor diagnosis only 8 (6) 9 (11) 3 (4) 61 (16)
Data are n (% of total available data within each column).
p-value b 0.05 was considered statistically significant.
a Seventeen patients had astrocytoma, 67 patients had oligodendroglioma, and 1 patient had oligoastrocytoma.
b Forty-two patients had anaplastic astrocytoma, 21 patients had anaplastic oligodendroglioma, and 4 patients had anaplastic meningioma.
c All patients had glioblastoma.
Table 1
Baseline characteristics.
Characteristics Total patients
(N = 662)
Patients without
seizures
(n = 379)
Patients with seizure as a
presenting symptom only
(n = 110)
Patients with seizure as a presenting
symptom and seizure after tumor diagnosis
(n = 92)
Patients with seizure after
tumor diagnosis only
(n = 81)
P
value
Age, years 56.1 ± 14.2 57.0 ± 13.8 54.9 ± 15.1 52.9 ± 14.3 57.2 ± 14.2 0.052
Male 354 (53) 183 (48) 70 (64) 58 (63) 43 (53) 0.007
Race 0.014
Caucasian 552 (83) 319 (84) 98 (89) 70 (76) 65 (80)
African American 77 (12) 37 (10) 7 (6) 21 (23) 12 (15)
Other 13 (2) 9 (2) 3 (3) 0 (0) 1 (1)
Unknown 20 (3) 14 (4) 2 (2) 1 (1) 3 (4)
Prior history of epilepsy 21 (3) 5 (1) 5 (5) 10 (11) 1 (1) b0.001
Data are n (% within each column) or mean ± SD.
p-value b 0.05 was considered statistically significant.
Table 3
Location of brain tumor and treatments received.
Total patients
(N = 662)
Patients without
seizures
(n = 379)
Patients with seizure as a
presenting symptom only
(n = 110)
Patients with seizure as a
presenting symptom and
seizure after tumor diagnosis
(n = 92)
Patients with seizure after
tumor diagnosis only
(n = 81)
P value
Location of tumor
Cortical region 583 (89) 320 (85) 106 (96) 86 (93) 71 (89) 0.004
Frontal lobe 299 (46) 160 (43) 53 (48) 50 (54) 36 (46) 0.248
Parietal lobe 169 (26) 87 (23) 27 (25) 23 (25) 32 (41) 0.017
Temporal lobe 221 (34) 120 (32) 43 (39) 31 (34) 27 (34) 0.620
Insular lobe 14 (2) 7 (2) 2 (2) 4 (4) 1 (1) 0.457
Occipital lobe 62 (9) 39 (10) 10 (9) 6 (7) 7 (9) 0.699
Cerebellum 13 (2) 13 (3) 0 (0) 0 (0) 0 (0) 0.018
Deep midline 24 (4) 19 (5) 1 (1) 2 (2) 2 (3) 0.144
Other location 99 (15) 58 (16) 11 (10) 19 (21) 11 (14) 0.205
Treatments
Surgery 634 (96) 355 (94) 110 (100) 90 (98) 79 (98) 0.019
Type of surgery 0.457
Total resection 223 (35) 123 (35) 35 (32) 35 (39) 30 (38)
Subtotal resection 256 (40) 146 (41) 48 (44) 30 (33) 32 (41)
Biopsy 138 (22) 72 (20) 26 (24) 24 (27) 16 (20)
Not specified 17 (3) 14 (4) 1 (1) 1 (1) 1 (1)
Chemotherapy with radiation 516 (83) 278 (81) 97 (91) 73 (83) 68 (86) 0.091
Chemotherapy 21 (3) 16 (5) 1 (1) 4 (5) 0 (0) 0.080
Radiation 45 (8) 27 (8) 6 (6) 5 (6) 7 (10) 0.722
MRI-guided laser ablation 6 (1) 5 (1) 0 (0) 0 (0) 1 (1) 0.437
Palliative care with hospice admission 148 (25) 62 (18) 24 (22) 26 (31) 36 (49) b0.001
Data are n (% of total available data within each column).
p-value b 0.05 was considered statistically significant.
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themwere prescribed anASD. Themost commonASDs prescribedwere
levetiracetam (47%), followed by phenytoin (34%), benzodiazepines
(5%), valproic acid (2%), lacosamide (2%), lamotrigine (2%), and
topiramate (2%), and other ASDs were used in the remaining 5% of
cases.
Surgical procedures were performed in 96% of all patients, of which
35% total resection, 40% subtotal resection, and 22% biopsy only, and 3%
without a specified type of surgery (Table 3). Patients without a seizure
were less likely to receive any type of surgery (94% vs ≥98%, P= 0.019).
Treatment modalities were not different among the seizure groups ex-
cept for admission to hospice that was more likely in patients who de-
veloped seizure only after BT diagnosis (49% vs. 21%, P b 0.001).
3.4. Survival and seizures
During12years of follow-up, 428 (65%) of the patients died. Theme-
dian OS was 27.7 months (95% CI= 23.3 to 32.1months) and varied by
tumor grade. The median OS was not reached for meningiomas and
grade II tumors, was 35.8 months (95% CI = 24.0 to 62.9) for grade III
tumor, and 17 months (95% CI = 15.7 to 17.9) for grade IV tumors. In
the survival analyses, seizures that occurred after tumor diagnosis
only were associated with higher mortality (adjusted HR: 2.11; 95% CI,
1.59–2.81; P b 0.001), in patients with WHO grade II (adjusted HR:
3.41; 95% CI, 1.05–11.1; P = 0.041) and grade IV (adjusted HR: 2.14;
95% CI, 1.58–2.90; P b 0.001) tumors. Seizures occurring at presentation
and after BT diagnosis were also associated with higher mortality (ad-
justed HR: 1.34; 95% CI, 1.00–1.80; P = 0.049) in patients with WHO I
(adjusted HR: 6.19; 95% CI, 1.30–29.4; P = 0.021) and grade III (ad-
justed HR: 6.19; 95% CI, 2.56–15.0; P b 0.001) tumors. On the opposite,
seizures that occurred as a presenting symptom only were associated
with better survival (adjusted HR: 0.27; 95%CI, 0.11–0.67; P = 0.004)
for patients with WHO grade III BTs (Table 4 and Fig. 1).
Additional variables included in the regression analyses were age,
gender, race, and parietal location. Cortical location was also associated
with both seizures and survival but was not included in the model be-
cause it was highly correlatedwith parietal location, which had a stron-
ger association with survival.
4. Discussion
This is the first study to analyze the association of seizures at presen-
tation and following the diagnosis in a diverse group of patients with BT
in relation to survival of these patients. In this large cohort of patients
with BT, we found that seizures occurred in 43% of patients. Of these pa-
tients, 17% had seizures at presentation only, 12% developed seizures
only during follow-up after tumor diagnosis, and 14% presented with
seizures and also had them during follow-up. Patients with seizure as
a presenting symptom were more likely to be male and younger. Pa-
tients who had seizures at presentation and during follow-up were
more likely to beAfrican American,more likely to have tumor in the cor-
tical area, and to receive surgery. Patients who had seizures only during
follow-up were more likely to have tumor in the parietal lobe, a prior
history of epilepsy, and admission to hospice after initial diagnosis. Pa-
tients with WHO grade II tumor had the highest rate of seizures either
as a presenting symptom or after tumor diagnosis in our study, which
was consistent with previous studies [9,13].
The majority of demographic and clinical findings in our patient
population corroborated with published research implying that a con-
ventional cohort was studied. The incidence of seizures in patients
with BT in our study (30% as a presenting symptom and 26% after
tumor diagnosis) was comparable with previous studies. Prior reported
incidence of seizures before or at the time of tumor diagnosis ranges
from14 to 51% [2,13–15] and the incidence of seizures after tumor diag-
nosiswas reported in 10–45% [2,14]. The higher frequency of seizures as
the first clinical presentation in patients with low-grade gliomas has
previously been reported [12], which is consistent with our findings.
Younger age and male predominance of patients presenting with sei-
zureswas seen in our study and is consistentwith prior studies showing
seizure as a presenting symptommost commonly seen inWHO grade II
tumor, which occur more frequently in younger patients [16], and gli-
oma, which occur more frequently in males [16]. In addition to age
and gender differences, we also found that African American patients
were more likely to develop seizures only after tumor diagnosis; we
did not have a clear reason from our data to explain this finding.
Tumor location and grading influence the occurrence of seizures.
Meningiomas, known to be the most common BT and are typically
Table 4
Association between seizure occurrence and mortalitya.
Patients with brain tumor Timing of seizure Unadjusted Adjustedb
HRc (95CI) P value HRc (95CI) P
value
All patientsd Seizure occurred as a presenting symptom only 0.90 (0.68–1.19) 0.452 0.90 (0.68–1.20) 0.488
Seizure occurred as a presenting symptom and seizure occurred after tumor
diagnosis
1.33 (1.00–1.77) 0.053 1.34 (1.00–1.80) 0.049
Seizure occurred after tumor diagnosis only 2.28 (1.73–3.00) b0.001 2.11 (1.59–2.81) b0.001
Patients with meningioma Seizure occurred as a presenting symptom only 1.53 (0.43–5.40) 0.512 1.34 (0.33–5.41) 0.685
Seizure occurred as a presenting symptom and seizure occurred after tumor
diagnosis
3.40 (0.96–12.0) 0.057 6.19 (1.30–29.4) 0.021
Seizure occurred after tumor diagnosis only 1.37 (0.18–10.5) 0.764 0.88 (0.11–7.20) 0.904
Patients with WHO Grade II
tumor
Seizure occurred as a presenting symptom only 0.37 (0.13–1.07) 0.066 0.44 (0.14–1.34) 0.146
Seizure occurred as a presenting symptom and seizure occurred after tumor
diagnosis
2.27 (0.06–1.25) 0.094 0.40 (0.08–2.03) 0.268
Seizure occurred after tumor diagnosis only 1.96 (0.65–5.90) 0.234 3.41 (1.05–11.1) 0.041
Patients with WHO Grade III
tumor
Seizure occurred as a presenting symptom only 0.58 (0.26–1.28) 0.175 0.27 (0.11–0.67) 0.004
Seizure occurred as a presenting symptom and seizure occurred after tumor
diagnosis
4.77 (2.07–11.0) b0.001 6.19 (2.56–15.0) b0.001
Seizure occurred after tumor diagnosis only 1.25 (0.17–9.33) 0.829 0.64 (0.07–5.62) 0.686
Patients with WHO Grade IV
tumor
Seizure occurred as a presenting symptom only 1.04 (0.75–1.42) 0.843 1.11 (0.81–1.53) 0.525
Seizure occurred as a presenting symptom and seizure occurred after tumor
diagnosis
1.25 (0.90–1.72) 0.180 1.26 (0.91–1.75) 0.165
Seizure occurred after tumor diagnosis only 2.31 (1.73–3.09) b0.001 2.14 (1.58–2.90) b0.001
p-value b 0.05 was considered statistically significant.
a Results from Cox proportional hazard regression with time-dependent covariate for seizures occurred after diagnosis.
b Adjusted for age at diagnosis, gender, race, and parietal locations.
c Reference group is patients without seizures.
d Stratified by tumor grade.
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benign, account for 1/3 of the tumors [17] with seizures in 1/3 of these
cases [18]. In our study, meningiomas contributed for 1/5 of the tumors,
and seizures were noted in 1/4 of these cases. An association between
tumor involving cortex and a high incidence of seizures was consistent
with many previous studies [13,19–22]. Patients with temporal lobe in-
volvement have shown to be at the highest risk to develop seizures be-
cause of high epileptogenicity of the mesial temporal lobe structure
[22,23]; however, our findings did not support this finding. Almost
half (40–60%) of the patients with BT located in each lobe (either fron-
tal, insular, temporal, parietal, or occipital lobes)were noted to have sei-
zures at some time in their life. Nevertheless, seizures occurring after
tumor diagnosis only were associated with parietal lobe involvement.
Patients with WHO grade III BT presenting with seizures and no
other seizure events thereafter lived longer even after adjusting for
age at diagnosis, gender, race, and parietal location. It is possible that
seizures at presentation in thosewithWHOgrade III BT aid in earlier de-
tection and treatment of the BT. Seizure were associated with longer
survival in patients with high-grade glioma and glioblastoma in previ-
ous studies [9,15]. Another theory is that seizure at presentation in
WHO grade III BTs may also reflect a phenotypic or molecular associa-
tion with grade II gliomas, which commonly present with seizures.
Data on seizure as a presenting symptom as a prognostic factor for
patients with meningioma are limited, and there is no association be-
tween seizure as a presenting symptom only and survival in patients
with meningioma in our cohort. Many previous studies supported that
the presence of seizure as a presenting symptom is also a favorable
prognostic factor for patients with low-grade glioma [10,24,25]; how-
ever, this has not been reproduced in all studies [9]. Patients with
WHO grade II gliomas who continued to have seizures after diagnosis
had worse outcomes in a prior study [10]. In our study, we demon-
strated an association between seizures that occurred only after tumor
diagnosis and mortality in patients with WHO grades II and IV BT, but
not in those with meningioma or WHO grade III tumor. However, we
did show an association between seizures at both time points (presen-
tation and during follow-up) and mortality in patients with meningi-
oma and WHO grade III tumors. Additional studies investigating the
rate and/or presence of tumor progression in patients who present
with and continue to have seizures during their disease, in meningioma
and WHO grade III tumors may shed light on this finding. Previous
studies support the hypothesis that ongoing seizures after surgical
treatment of tumor have an association with tumor progression in pa-
tients with low-grade gliomas and malignant astrocytomas [4,26]. No
prior study has been conducted to demonstrate an association between
the occurrence of seizures after tumor diagnosis and survival of patients
with high-grade BT.
The major strength of this study is long-term follow-up (up to 12
years) of a large cohort (N = 662) of patients with a diverse represen-
tation of primary BT histologies including glioma and meningioma.
We also were able to illustrate the prognostic significance of seizures
that occurred after tumor diagnosis. This study has limitations. This is
a single center retrospective study, with 21% of the initial cohort ex-
cluded for insufficient data, which may limit the generalizability of
study results. Second, we lack information on functional status at the
time of tumor diagnosis, which has been shown to influence survival es-
pecially in high-grade tumors. Finally, information of the effectiveness
of seizure control was not available; it is possible that uncontrolled
seizures might affect patient outcomes.
5. Conclusion
Seizures occur in almost half of patients with BT. The association be-
tween seizures in patients with BT and their survival depends on the
time of occurrence of seizures, if occurring at presentation or after
tumor diagnosis, and the type of BT. This is the first study to correlate
seizures as a presenting symptom only of BT to better survival in
WHO grade III BTs while higher mortality to WHO grade II tumors
Fig. 1. Survival curves in different types of brain tumors in patients with (A) meningioma, (B) WHO grade II brain tumors, (C) WHO grade III brain tumors, and (D)WHO grade IV brain
tumors, shown in the four groups:with no seizures (black solid line),with seizures only at presentation (blue dashed line),with seizures at presentation and after diagnosis (green dashed
line), and with seizures only after diagnosis (red dashed line). (For interpretation of the references to color in this figure legend, the reader is referred to the web version of this article.)
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presenting with seizures that continue after tumor diagnosis and to
WHO grade IV tumors with seizures after diagnosis. As the relationship
between seizures and tumor phenotype (grade, behavior, and survival)
is further elucidated, clinicians may be able to improve HRQOL and OS
through improved seizure control and/or prevention. We propose that
the time of seizure occurrence during the course of BT diagnosis might
be another valuable tool in predicting the disease progression of those
impacted by BTs and possibly help in earlier detection andmanagement
for longer survival of these patients.
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